N
Google TrendLAMINE YAMAL (2000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "SGLT2-GLP-1 Combo Little" (28 stories)

Top Headline Story

SGLT2-GLP-1 Combo Little Better Than Monotherapy in T2D
Lead StoryMedscapegeneral
Jul 24

SGLT2-GLP-1 Combo Little Better Than Monotherapy in T2D

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOUjRLX3pVSmJ6TkdNOGIyRE5WcV93bU02WTFSUTdvYk02YjU0ZklobzlXUTZrWExyLXNUSFl3WWFLZ2xXb2NzYW14cTA3WTdwenRCTjRlaXNVb0ZveUh5ZHItb0gyNHhHOTRYcHpsQU5jRlZKVEt5YUlUOG9wU0Q5ZmdXNm1yNFFESGluWlRNRk1FYzg4TkFIV1VHdFFzcmZFOGhvYw?oc=5" target="_blank">SGLT2-GLP-1 Combo Little Better Than Monotherapy in T2D</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+21m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+31m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories
500+31m ago

pope francis

The Myth of St. Francis

Filter stories
500+31m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "SGLT2-GLP-1 Combo Little"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

27 stories displayed
Combo GLP-1 RA, SGLT2 Therapy Linked to Lower Kidney, CV Risks
The American Journal of Managed Caregeneral

Combo GLP-1 RA, SGLT2 Therapy Linked to Lower Kidney, CV Risks

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNVjRXdFU5QTJFRXJ2dkdBdmV3b3E1TjdQY1daRG9qUlAyMzNTYmk4SHBHa0lzZk8tcE0tYXpQN2VPcXFoOE5ITlFHMmZUcXg1Mjkza0l3SjZzSDBidUhRdUk5bS1ORy13T3VodENXSHhwY1A5V1F2TThJaG5Ydi1SQzExOEE5R0hqbkVRX1RHZw?oc=5" target="_blank">Combo GLP-1 RA, SGLT2 Therapy Linked to Lower Kidney, CV Risks</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial
Naturegeneral

Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE52MFloNThjMTNyNTFBZG5XdW1vZ2hpRndsOUhQaV9EMUg2Vy1mUTVHcVAxWldmcXlhOENzSm1mdl9HM1pRc3JQLTI1eGtLVTJmYWQtbmd1dEJ4M1cwMDFZ?oc=5" target="_blank">Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Frontiersgeneral

Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQeDdpQmhjc3lRY0JoZDdzVTQ0Q1dNZ01qNng5M0RZWDBWaWJuNG5sSWRJam9KQUl4emc3ejV6bi0tM2tKRnRxVjl2UzVFelI5UkRsUmJ3MERsSEs1dFJGMGhaUmRTbG5sOEdHeDRJYWRCRkZZRjBReUw5M05idE5uOVhWUFo3bmJvWkVzZzJXdURFdVVv?oc=5" target="_blank">Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis
CMAJ | Journalgeneral

Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE40eHNVWWFwVURRaEV1NWs5NzhReDVFOGlCX19ZaGJDeW9qRzJ6SnFpRGlGT29zQ2Z4S1Nsa1RndV9YRkRSdjZuWmR0MldaUHd5?oc=5" target="_blank">Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis</a>  <font color="#6f6f6f">CMAJ | Journal</font>

Read Full StoryMore like this
Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?
Cureusgeneral

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

<a href="https://news.google.com/rss/articles/CBMi3wJBVV95cUxPMm84aGZqdzlrbS00WFJLaDkxVzVIdDBMNTJxWWRocnJuWUt4VkR3dnZ0MnRNNG10LXM2NVNfXzBaLTFubGdEYU1NTnd1ZDhra2xuV2w2QUhiSWxseF83ZmFUbVRQak85UW44d1pFbkN1Y1BOeVR2bkY4YjdqeWhzVmZ0UVN0Qk9qQU95bVRIM2tkTmVjckZCbDVGcE1hQXpjODUwMl9aYUVtdU9pQnNDWEQ4QW40RmdaYkR0eHpNNVZkQVd2QlFHeUstcmlYRnh3dFBuYlhLeVExMW9NbTd5NGZYc0NaQ2pQd3NCb08yUG5wY0FNcGh5RTRlVUFkTzRNMGJ5MHpPb3dkR0NiSWpnTEZpS0laemFfdTdqazI1UDZ2OVhKeklyZThTUHhmYTRfVzY4ZGR3enk5WDBCMHpISUczT1NrYVQ2d2U3M01KZ243WUtvcTJRdTd0alpVaGs?oc=5" target="_blank">Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1–40 in diabetes
American Physiological Society Journalgeneral

GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1–40 in diabetes

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1JM2J2R1Z0MUc3QnRpTFpKcG9EbEFpeDVGcjlmUUxOWEw3dVdhQXMzM25mQndVMWV1YWlwQ2JSU1oycXNNdEtNMVdPenlud1VfeEtXbzZ0T2otYW5yYlNvNFBBcmh4d3luRHZEejF4dGZDbUhKZVRB?oc=5" target="_blank">GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1–40 in diabetes</a>  <font color="#6f6f6f">American Physiological Society Journal</font>

Read Full StoryMore like this
Two Diabetes Drugs, One Powerful Punch: Real-World Data Reveal Semaglutide Plus SGLT2 Inhibitor Benefits
Bioengineer.orgworld

Two Diabetes Drugs, One Powerful Punch: Real-World Data Reveal Semaglutide Plus SGLT2 Inhibitor Benefits

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOTlN4bzFKeEpHcXJJbzI1VjVQQnBTNlpaYm83bEtQUlhydzJJbEJVN1hXV0E4TVMxLS1EQVMtWmRmWEVxZTZBNkNHdm0tU1FqU0tQRGhzbFpfT21JeXhyY1AxMEpzbnl0MVdKUUtLS3A1LUlFNkpyYjVRTFg5ajZieUFYdTZnaEFMQlBFWFlET1FQbnFLQmQtQ3hBMHp1YVBxQ0RpRHUwelZTN1JwQXZKc2p0Z290ZXdBNVFCN2xMMFFGb2ZCc0E?oc=5" target="_blank">Two Diabetes Drugs, One Powerful Punch: Real-World Data Reveal Semaglutide Plus SGLT2 Inhibitor Benefits</a>  <font color="#6f6f6f">Bioengineer.org</font>

Read Full StoryMore like this
Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes
Naturegeneral

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE02Y2hLWlBfSVpYb282eFZzMFVJUTNCN1FpejFTcVZUWlpQbzJGa3dtazRGSm1xbmVzWTIwak13VmQtX2tVbE5qQVU4d29kNmZVN2g5U3NheEhYaU4zV2t3?oc=5" target="_blank">Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies
Frontiersgeneral

Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPQ0Y1Nkp2MkxKV2dNMnMxNVZURFlNRGd5bmFXSm1fdjdaaUd4NzlfYjRSVkQzaEtfOG5NZW9uZlBuWWhrUG1OQV9NZXgtQWZJUGRFQXpuaG1pMi1fSDZnRGtGRjdBbVdOR2pBNEdQRmpEdmRRWTJvcElCVHI3QVo5OXVjNDJXZm4ySFBXV1FibDRDcEJIT1E?oc=5" target="_blank">Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases
Naturegeneral

Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBocWdJdW1jUVhQUU5YUUxYOXZGQUZ0bWUzUWc5c1AzelA0clQ3UDloQWt0X2dlMGpWS2lyeUdWX2djUVIxYVRDRkpDYmZJUFJUWEJhNE9XUV8wMzBlVXQ4?oc=5" target="_blank">Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Study Estimates Lifetime Benefit of SGLT2, GLP-1 RA, Nonsteroidal MRA Use in Type 2 Diabetes
HCPLivegeneral

Study Estimates Lifetime Benefit of SGLT2, GLP-1 RA, Nonsteroidal MRA Use in Type 2 Diabetes

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOGM4dHUycHg4Z09aVTBya0NsNHdsRE55cjJBUmttcW0tcmZkWHFtbGpjbVVKcDFSWmpTRTZ3Nm5PbGxnUjM0cFZwdlY3QThNaDlkU0MyYnQ2UXE3WndUTExHb2hMN0ExRFY2SnBGVF9JSGx2Rjh3dnZCTzBhTGtvRlVZX1ZIcjVoTEdOUTJQbjh1V2t0NGxyZUQzNGsyblZZVnFrME5zeW1JX1hEZmZyYTlIa1VfWWI4ZGNB?oc=5" target="_blank">Study Estimates Lifetime Benefit of SGLT2, GLP-1 RA, Nonsteroidal MRA Use in Type 2 Diabetes</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF
American College of Cardiologygeneral

GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQZjVKTDZtRHlFampWUkZueVA4TmQwamozMHZ2QWY3dVcxSjdFb3JQY0s5SE5iRkU5Wk1ra0d1REVwaHV3cjNUa0lRMlhCazMta1RuOFRiTmNhazRKWHJZVlZFTjM0MEJNSGo3MEd0NXJremxHRGl0R0hma0YyOE1YbEJqYmVNUE1DaXA1Z2M4MHJ6a1F6UmpqUTBDTkhDYmxObGc?oc=5" target="_blank">GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF</a>  <font color="#6f6f6f">American College of Cardiology</font>

Read Full StoryMore like this
AstraZeneca launches GLP-1 combo to treat obesity co-morbidities
Pharmaceutical Technologyworld

AstraZeneca launches GLP-1 combo to treat obesity co-morbidities

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQNTZnblBWcXhhZEFucVRGdnc4VFZJYms1Ri1QaHBidHI5cXZ2TV93YXN4clVvSk4tbzJTV1JqQ1pkeFpvNndRVHV3eGlVdEtQRzByZS1NSHBhODVqMS1sb0pRejIxMmRWX1FtZ2w3bGtxaGh2VUlNNFhtYTNyVnREU21NZTN3U0wtUUJ1Q0JtVEV2N1hiZEs4d0VtMXpzRU9u?oc=5" target="_blank">AstraZeneca launches GLP-1 combo to treat obesity co-morbidities</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
Endocrinology Advisorgeneral

SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNRzNGOGJJLW5OaGNBNkd3ME4ybGtWSEZiUmsxeGFuOGRhN1VGWHBIRWlSRmZmajdDNUNlQkFHR0dwUXV1RFVLTjR3dUxJNlNpZ29RVTh0aEtna2JjRlhCWnRzY0pIWnZraFlNX0dnSk9xQ1FlcDVFN1otN2hfRy0tSUJsMG85M2U0X3R6aVhadW9YMWpBNnJLbDZuZ2pqbk1fX211Q2JxaXpYVU8tOGxnVEJwaDM0S2JoY245WmZsaWROQU1QOUMyVVVqcTdRZHBfWUlkRjZHaTFWclU?oc=5" target="_blank">SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights</a>  <font color="#6f6f6f">Endocrinology Advisor</font>

Read Full StoryMore like this
Beyond Diabetes: SGLT2 Inhibitors in Heart Failure, CKD, and in Combination With GLP-1 RAs
The American Journal of Managed Caretech

Beyond Diabetes: SGLT2 Inhibitors in Heart Failure, CKD, and in Combination With GLP-1 RAs

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPb0Q3Rkxpbm10R1Y1UUJKWjBIM1gwejlUVERyMVdNdkZqS0V3aERwUnVubklCX01hZkcxMmVNbzQ0OWdPZnV6Q0dQeGJzczhLZlRjQ2l5b052c0NtUVl2SlV3YjBfekphX1I4bkhiWWhBNE02dm9KZDdERHRIRmNSQXUyWDQ3TWlsM2ZoNmdzekNaUTZGbUNPTHF4UVBMWm5iQ0xNNjdwZ2JpcWg1a3A3SnhpVQ?oc=5" target="_blank">Beyond Diabetes: SGLT2 Inhibitors in Heart Failure, CKD, and in Combination With GLP-1 RAs</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review
Frontiersgeneral

Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPZ1kyWjlxZVlXSms5QlFrcGoxMWU3bjBGbGRVSnprblJPQlA0UzlnN3FZLWYyZ3ZNSVlCZkdjdEwtZHdreUNtbkRFcXJVZGFRNTlHQjR1eWpOZnpmWkttekpVaUJ1TUw1UjFHZTBORXhsWWFad2pFbWYxQWRBdm5LQlhqTkptc21OUGFLZXZHYUhPa0FEeUE?oc=5" target="_blank">Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy
Naturegeneral

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBrblBnd2pwWm5YN2RsN2h1ZkkwU3d1b25oT1NwY3k1ajBsVGxkNlZyWmwwTC02NFVlNzQyR013N29EaTBMUjRRWW54aHpjdUVwbFNuQ0RheVdXaEhJbEdn?oc=5" target="_blank">Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
Naturegeneral

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9pY0hxQ1E1UlFkOTdOcm1mV0tRcVZ2MjFRbWt4eWxEdXR3UU4zMVU2bUN6dWRYNHdnTXNPYklVSmt0d3p4THAtZDRMU0lrcnMtZXRwOEktNGp3WW1XQWZN?oc=5" target="_blank">Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus
Naturetech

Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9JQkluZkhFMlh2OFZWS0RFRVluMTY0SjJwZmp5bWRCaWxNMjJhQi02QjM3aXAteXk4UGd0bWdKcEZRY0lfd1BGcmxtazZLdWpXNjhLc0ROQzNsOVg3RVVj?oc=5" target="_blank">Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes
Healiogeneral

Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSk9FZHR0dmdhVTZwS094a2RpOVV3YmhRVGVkQ09OanJBODlBMnZlNVg3YVZBMUJQMHhCNzRVVmN2ZVNfRVdaSDZ4MWtrS09ZTlpQNDR1ck9nZlRVSV9yMTMteE9mTmlxeU1IUkZxNzNnT1lNZXRtSk1mRVNCSkphOEJhMkIwRmxsUXZIVkJSWVdKNF9LVVVmWS1hWUtPRnAyd1R4TXUwcHE2WFBRbXc5RWVSSEZaNVhzcElQNjg1UlNXZEJlekVnRzRNSjdVNU5Md3c?oc=5" target="_blank">Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes</a>  <font color="#6f6f6f">Healio</font>

Read Full StoryMore like this
7 Popular Combination Diabetes Medications for Treatment
GoodRxgeneral

7 Popular Combination Diabetes Medications for Treatment

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQbFVUTE5HX0M4RzBLTzI5M0dkWUxkakxvckdHSEQzdkhXMDJ5ZlFBTlFoVC12cDVnN0htOV9sNFp3WkdlU2txeXpUQkFiYWhsSnVVV2VyWmN6bXU0cVBiRFpUUHZhejM2Rmp5ZldQWnpCLWlvQjE1Q3oyM19MS0Z4d1B1TzIySEpY?oc=5" target="_blank">7 Popular Combination Diabetes Medications for Treatment</a>  <font color="#6f6f6f">GoodRx</font>

Read Full StoryMore like this
Hanmi Pharm files phase 3 IND for GLP-1 combo in type 2 diabetes
Korea Biomedical Reviewgeneral

Hanmi Pharm files phase 3 IND for GLP-1 combo in type 2 diabetes

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5mQ2dsODR1RzdMczJSNEhBMThyTUxrZE42SU4wTlI0Mll2YmxBbFRkcnAxSElQUVBULW1PalZfd0VBMVlFc004cVVYd2R2WjVmR0tqMW1faTY2S25kWjJTNFBqTmZUZDM5Y0VGVHVB0gFyQVVfeXFMTTgwU25qQjZNeFowUkxvR0xZM0p4X0dlNlI2UFhSbXF5LV9jbmYzdTd1TmdMTUsta3lrTlM1eU5DaVRRaXhoaS1OS0t5UkJjaWd3a1I4SFdsbWIxR2FWUHhaazNfOHZxRGR1LWtDMDBST2lB?oc=5" target="_blank">Hanmi Pharm files phase 3 IND for GLP-1 combo in type 2 diabetes</a>  <font color="#6f6f6f">Korea Biomedical Review</font>

Read Full StoryMore like this
AstraZeneca talks up potential for obesity combo treatments, insists it's 'playing to win' in crowded field
Fierce Biotechgeneral

AstraZeneca talks up potential for obesity combo treatments, insists it's 'playing to win' in crowded field

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZGJWeUItSU1hM3RXYVZhYlFpdFlEYkNZUk1nSzRMcWJ2U0ZzTlpJMTJfd250TEhtb25CY3hSX0xVbG1FRzdPLXF0M1J1ZnA3cmYzZjJMeUJHUGZBYkNBUmYxNW1Da1NGUnhnX05JVWpqVlBFaUV0eXE3WkdSeHpFOFBPRmFXWFhTOXM1UGpwblMtdmYzOHoteU52NWRVZzFYZW02ZTVMVlpfcTg?oc=5" target="_blank">AstraZeneca talks up potential for obesity combo treatments, insists it's 'playing to win' in crowded field</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease
Drug Topicstech

SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQYmoyUnNrZDN1Mmd0QWppUXJEVnQ4M2NVYWdQM1BnTEN3a1FiSkZDUTZtMDEyU1VCU2tsMWdmeGNaYVdaQWhpaU9rQWg1NHkzYl9aRWJaN3JYbWhXNFByUWFNeEJzWGhET1RtUzVIZjdGUzBJb0YwSE5jZ2JjLTBicEFKd1BPNTJlS1A4TGtXTzktdVJXdDNZRXp3NTN4REItNS1qWHdSdVhMQ19PLWNHYVNfdklhdVEzNzZReDNvTHV1VXd5MVJGUQ?oc=5" target="_blank">SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease</a>  <font color="#6f6f6f">Drug Topics</font>

Read Full StoryMore like this
Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes
Fierce Biotechgeneral

Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS3h0WHpFWkxQQUF0WndUMEVEVlQ4SEQzZUdmQUZSQ2RlamxnTUtZZVhrbGRtZHdxNFdiWDFIXzNoN3BSM25jRWQ5bUpGMWs0bko2RUtNdWpsRDJFcVRrdjJCSkxpVWNSSnFtOW9pLTdBam5HWHB0eVNaTzNWN3RHdU5NVWRyUm9pb1Q4bUNMWnczRUtyQnpEOVZ1WUk1U05XQ0dNOHpmZXlYVUtGZk5pc0g1R1E2SnpRQXBj?oc=5" target="_blank">Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
ADA Guidelines Recommend Earlier Combination Therapy
Diabetes In Controlgeneral

ADA Guidelines Recommend Earlier Combination Therapy

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPZFh0UUo2Z3I4WEl5cDlCX2VVdjdrR3pXUUxtV0ZFU0V6T0JTWG9HaTdaMW8zNUxoWGtkV0EtaC1KVUUyM1o3WmdybDA5VXBRdXpLSHB6SEtUOXBQUGdBdE9SemhUa1RXZmtmVlJxSm90X3JPYzNPdUYxQ1FrQnpPUVhZVHpTMmZ0VU9PQ3h0LUI?oc=5" target="_blank">ADA Guidelines Recommend Earlier Combination Therapy</a>  <font color="#6f6f6f">Diabetes In Control</font>

Read Full StoryMore like this
What to Do If Metformin Fails To Get Patients To Target
Diabetes In Controltech

What to Do If Metformin Fails To Get Patients To Target

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOZHVrQmZFb3ZMOTdlVmdrNWd1eUxEOFRtaFpWRHkxNzJhZFEwQ09rTVd3eGUwYmE1Y184bGhLSUFqV255eTY5S29tSUtUSk9Vb09SUWllTUhabHlQVzVQZ3djUkZ5R0hBd3l3ZWZpM3Fycm9pYzJuUlJLdzM0aXBmWG0yT0l1Q0hndmU1Vld2TXNXVkR2UEt6Si1sYkVQU09melF3?oc=5" target="_blank">What to Do If Metformin Fails To Get Patients To Target</a>  <font color="#6f6f6f">Diabetes In Control</font>

Read Full StoryMore like this
"SGLT2-GLP-1 Combo Little" — Live Google News Trends & Headlines